Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -1.72% | -1.72% | -35.23% |
May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Financials (USD)
Sales 2024 * | 10.54M | Sales 2025 * | 14.69M | Capitalization | 83.18M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -62M | EV / Sales 2024 * | 7.89 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.66 x |
P/E ratio 2024 * |
-1.71
x | P/E ratio 2025 * |
-1.7
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Cue Biopharma, Inc.
1 day | -1.72% | ||
1 week | -1.72% | ||
Current month | -10.00% | ||
1 month | +4.91% | ||
3 months | -21.92% | ||
6 months | -29.34% | ||
Current year | -35.23% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +3.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.71 | -1.72% | 117,895 |
24-05-16 | 1.74 | +6.10% | 278,368 |
24-05-15 | 1.64 | +5.81% | 263,507 |
24-05-14 | 1.55 | -6.06% | 614,521 |
24-05-13 | 1.65 | -5.17% | 98,120 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.23% | 83.18M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CUE Stock